Comparing two treatment combinations for relapsed lymphoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness of zanubrutinib combined with obinutuzumab against lenalidomide combined with rituximab in patients with relapsed or refractory follicular lymphoma and marginal zone lymphoma. The primary measure of success will be progression-free survival, assessed by an independent review committee using advanced imaging techniques. Participants must have previously received systemic therapy and show a need for further treatment. The study aims to provide insights into which treatment combination offers better outcomes for these specific lymphoma types.

Why it matters

Who can join: the full rules

Key Inclusion Criteria:

* Histologically confirmed grade 1-3a FL or MZL
* Previously treated with ≥ 1 line of systemic therapy including anti-CD20 agent. Must have a documented failure to achieve at least partial response during the most recent systemic therapy or documented progressive disease after the most recent systemic therapy
* Need for systemic therapy for FL or MZL
* Measurable disease by computed tomography or magnetic resonance imaging
* Adequate bone marrow, liver and renal function

Key Exclusion Criteria:

* Transformation to aggressive lymphoma
* Requiring ongoing need for corticosteroid treatment
* Clinically significant cardiovascular disease
* Prior malignancy within the past 2 years
* Active fungal, bacterial, and/or viral infection that requires systemic therapy
* Prior treatment with lenalidomide or drug from same class, if without response (partial or complete) or short remission duration (\< 24 months)

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Where it's running

• Aichi Cancer Center Hospital Clinical Oncology
  Nagoya, Aichi-ken, Japan Recruiting
• Chiba Cancer Center
  Chiba, Chiba, Japan Recruiting
• Matsuyama Red Cross Hospital
  Matsuyama, Ehime, Japan Recruiting
• Hiroshima Red Cross Hospital and Atomic Bomb Survivors Hospital
  Hiroshima, Hiroshima, Japan Recruiting
• National Hospital Organization Hokkaido Cancer Center
  Sapporo, Hokkaido, Japan Recruiting
• Aiiku Hospital
  Sapporo, Hokkaido, Japan Recruiting

+227 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Principal investigator: Study Director — BeiGene
• Study coordinator: Study Director BeiGene
• Email: clinicaltrials@beigene.com
• Phone: 1-877-828-5568

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Zanubrutinib, rituximab, lenalidomide plus tislelizumab for relapsed/refractory follicular lymphoma

  This trial tests whether adding the PD‑1 blocker tislelizumab to zanubrutinib, rituximab, and lenalidomide helps adults with relapsed or refractory follicular lymphoma who have had at least two prior therapies.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07418190

• Zanubrutinib plus rituximab as first-line treatment for marginal zone lymphoma

  This tests whether combining zanubrutinib and rituximab is effective and safe as first-line treatment for people with CD20-positive marginal zone lymphoma who have not received prior systemic therapy.

  Recruiting Henan Cancer Hospital · Zhengzhou, Henan · NCT07233720

• Combination treatment for relapsed or refractory follicular lymphoma

  This study is testing a new combination of three medications to see if it can help people with relapsed or refractory follicular lymphoma feel better.

  Recruiting at 3 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 2 other locations · NCT06563596

• Combining rituximab and zanubrutinib for treating indolent B-cell lymphomas

  This study is testing if combining two medications, rituximab and zanubrutinib, can help people with untreated indolent B-cell lymphomas feel better and improve their treatment outcomes.

  Recruiting Phase 2 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida · NCT06350318

• Polatuzumab vedotin with Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in untreated DLBCL (MCD/BN2/N1)

  This study tests a targeted combination therapy to see if it can treat previously untreated DLBCL with specific molecular subtypes.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07608978

• Nemtabrutinib plus rituximab for marginal zone lymphoma

  This phase 2 trial tests whether combining nemtabrutinib with rituximab can help people with marginal zone lymphoma.

  Recruiting Phase 2 City of Hope Medical Center · Duarte, California · NCT07583810

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.